Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 180 clinical trials
Featured trial
VastBiome: The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods …

programmed cell death 1 ligand 1
targeted therapy
cancer chemotherapy
  • 28 Feb, 2022
  • 1 location
Featured trial
Phase 1 study of BAY1905254 - An early clinical research study to evaluate a new drug called Bapotulimab (BAY1905254) in the expansion cohort in combination with Pembolizumab in Head and Neck cancer that has returned or is discovered to be metastatic and is expressing PDL1.

This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab.  The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it affects the body and to try to find the best …

squamous cell carcinoma
metastatic head and neck cancer
primary tumor
  • 14 Sep, 2021
  • 8 locations
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03)

with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI). The primary objective is to determine whether tusamitamab ravtansine improves the overall survival

measurable disease
squamous non-small cell lung cancer
platinum-based chemotherapy
  • 29 May, 2022
  • 210 locations
Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions

This trial is designed as a prospective, multi-centre, open-label, single-arm, phase II study. Oral Premalignant Lesions (OPL) may be considered the equilibrium phase of the immunoediting concept, i.e. a dynamic process between the tumour cells and the immune system including surveillance by the immune system or tumour progression. Thus, an …

  • 27 Jan, 2021
  • 5 locations
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.

This is an open label single arm phase 2 clinical trial in patients with metastatic solid malignancy of any histology who have previously experienced limited progression in at least 1 and up to 5 lesions while on immune checkpoint inhibitors monotherapy.

  • 06 May, 2022
  • 1 location
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open Multi-center Phase II Clinical Trial

according to the patient's wishes and the evaluation of the surgeon. After the operation, they were randomized and the experimental group accepted PD-1 immune checkpoint inhibitor treatment (microwave

  • 30 Sep, 2021
  • 6 locations
Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

The FOLFIRINOX regimen has become the standard treatment regimen for advanced colorectal cancer, advanced pancreatic cancer and postoperative adjuvant treatment for pancreatic cancer. With the continuous exploration of Chinese scholars, it has also revised the modified dose suitable for the physical fitness of the Chinese people, which is well tolerated …

  • 09 Jun, 2021
  • 1 location
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

  • 24 Mar, 2022
  • 1 location
Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors

to further analyze the efficacy and safety of OVV-01 injection combined with immune checkpoint inhibitor injection in the treatment of advanced solid tumors.

breast cancer
primary cancer
bone marrow procedure
  • 09 Jul, 2021
  • 1 location
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Combination of anti-angiogenic molecular targeted therapy and anti- programmed cell death -1 immune checkpoint inhibitor (ICI) therapy has shown promising antitumor activity in multiple cancer

  • 28 Jan, 2021
  • 1 location